Given investment horizon of 30 days, Nektar Therapeutics is expected to under-perform the Adamis. But the stock apears to be less risky and, when comparing its historical volatility, Nektar Therapeutics is 2.98 times less risky than Adamis. The stock trades about -0.17 of its potential returns per unit of risk. The Adamis Pharmaceuticals Corporation is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest 71.00 in Adamis Pharmaceuticals Corporation on April 26, 2012 and sell it today you would lose (6.00) from holding Adamis Pharmaceuticals Corporation or give up 8.45% of portfolio value over 30 days.
Diversification
Average diversification
Overlapping area represents amount of risk that can be diversified away by holding Nektar Therapeutics and Adamis Pharmaceuticals Corp. in the same portfolio (assuming nothing else is changed)
Over the last 30 days Adamis Pharmaceuticals Corporation has generated negative risk-adjusted returns adding no value to investors with long positions.
USA 
Select Assests
Optimize Portfolio
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatilities
Import Equities
Search Equities
